Evaluation of BCL6 and MUM1 Expression in Patients with Diffuse Large B Cell Lymphoma (DLBCL) and Their Correlation with Staging and Prognosis of the Disease

Rahimi, Hossein and Jafarian, Amir Hosein and Samadi, Alireza and Meamar, Bahram (2015) Evaluation of BCL6 and MUM1 Expression in Patients with Diffuse Large B Cell Lymphoma (DLBCL) and Their Correlation with Staging and Prognosis of the Disease. Journal of Patient Safety & Quality Improvement, 3 (1). pp. 198-200.

[img]
Preview
Text
PSJ_Volume 3_Issue 1_Pages 198-200.pdf

Download (254kB) | Preview
Official URL: http://psj.mums.ac.ir/article_3814.html

Abstract

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin Lymphoma (NHL) which includes about (25) of the cases. Patients with DLBCL have a rapidly growing mass that is located in the neck or abdominal region. Multiple Myeloma Oncogene (MUM1) has an important role in lymphoid cell differentiation. MUM1/IRF4 is as oncogene related to myeloma and translocation (p25; q32), t (6; 14) and leads to a change in the heavy chain of Immunoglobulin (IGH). BCL6 exists in approximately (100) of follicular cell cancer cases, (100) of Burkitt lymphoma, (80) of large B-cell lymphoma, and in more than (80) of nodular lymphocytic Hodgkin lymphoma cases. BCL6 is related to cancers with a high proliferation cell index. In some studies BCL6 is expressed as a prognostic factor in LBCL patients

Item Type: Article
Subjects: W General medicine- Health professions
Divisions: Journals > J Patient Safety & Quality improvement
Depositing User: psj psj
Date Deposited: 27 Sep 2017 13:25
Last Modified: 27 Sep 2017 13:25
URI: http://eprints.mums.ac.ir/id/eprint/5087

Actions (login required)

View Item View Item